Production (Stage)
Protagenic Therapeutics, Inc.
PTIX
$3.62
$0.1353.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.05M | 1.76M | 1.22M | 1.24M | 1.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.41M | 5.70M | 5.27M | 6.05M | 5.53M |
| Operating Income | -5.41M | -5.70M | -5.27M | -6.05M | -5.53M |
| Income Before Tax | -5.24M | -5.53M | -5.65M | -6.40M | -6.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.24 | -5.53 | -5.65 | -6.40 | -6.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.24M | -5.53M | -5.65M | -6.40M | -6.01M |
| EBIT | -5.41M | -5.70M | -5.27M | -6.05M | -5.53M |
| EBITDA | -5.36M | -5.65M | -5.21M | -6.00M | -5.49M |
| EPS Basic | -13.31 | -16.00 | -17.83 | -20.36 | -19.21 |
| Normalized Basic EPS | -8.53 | -10.21 | -10.24 | -11.82 | -10.76 |
| EPS Diluted | -13.31 | -16.00 | -17.83 | -20.36 | -19.22 |
| Normalized Diluted EPS | -8.53 | -10.21 | -10.24 | -11.82 | -10.76 |
| Average Basic Shares Outstanding | 1.61M | 1.40M | 1.27M | 1.26M | 1.25M |
| Average Diluted Shares Outstanding | 1.61M | 1.40M | 1.27M | 1.26M | 1.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |